Core modification of cytisine: A modular synthesis

Angewandte Chemie - International Edition

Volumn 50, Issue 22, 2011, Pages 5162-5165

  Hirschhäuser, Christoph ^a   Haseler, Claire A ^a   Gallagher, Timothy ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

acetylcholine receptor; cytisine; heterocycles; pyridone; varenicline

Indexed keywords

ACETYLCHOLINE RECEPTOR; CYTISINE; HETEROCYCLES; PYRIDONES; VARENICLINE;

ALKALOID; AZOCINE DERIVATIVE; BENZAZEPINE DERIVATIVE; CYTISINE; NICOTINIC AGENT; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR ALPHA4BETA2; PYRIDONE DERIVATIVE; QUINOLIZINE DERIVATIVE; QUINOXALINE DERIVATIVE; STANNANE; TIN DERIVATIVE; VARENICLINE;

ARTICLE; CHEMISTRY; CYCLIZATION; METABOLISM; SYNTHESIS;

ALKALOIDS; AZOCINES; BENZAZEPINES; CYCLIZATION; NICOTINIC AGONISTS; PYRIDONES; QUINOLIZINES; QUINOXALINES; RECEPTORS, NICOTINIC; TIN COMPOUNDS;

EID: 79956095918     PISSN: 14337851     EISSN: 15213773     Source Type: Journal    
DOI: 10.1002/anie.201100441     Document Type: Article

References (36)

1. A. A. Jensen, B. Frølund, T. Lijefors, P. Krogsgaard-Larsen, J. Med. Chem. 2005, 48, 4705-4745. For leading references to nicotinic pharmacophore studies see
2. R. A. Glennon, M. Dukat, Bioorg. Med. Chem. Lett. 2004, 14, 1841-1844
3. J. E. Tønder, P. H. Olesen, Curr. Med. Chem. 2001, 8, 651-674.
4. J. W. Coe, P. R. Brooks, M. G. Vetelino, M. C. Wirtz, E. P. Arnold, J. Huang, S. B. Sands, T. I. Davis, L. A. Lebel, C. B. Fox, A. Shrikhande, J. H. Heym, E. Schaeffer, H. Rollema, Y. Lu, R. S. Mansbach, L. K. Chambers, C. C. Rovetti, D. W. Schulz, F. D. Tingley, B. T. O'Neill, J. Med. Chem. 2005, 48, 3474-3477
5. J. W. Coe, H. Rollema, B. T. O'Neill, Annu. Rep. Med. Chem. 2009, 44, 71-101.
6. Natural cytisine has also been used extensively within Eastern Europe for smoking cessation., J. F. Etter, Arch. Intern. Med. 2006, 166, 1553-1559.
7. P. Imming, P. Klaperski, M. T. Stubbs, G. Seitz, D. Gündisch, Eur. J. Med. Chem. 2001, 36, 375-388
8. E. Marrière, J. Rouden, V. Tadino, M.-C. Lasne, Org. Lett. 2000, 2, 1121-1124
9. S. K. Chellappan, Y. Xiao, W. Tueckmantel, K. J. Kellar, A. P. Kozikowski, J. Med. Chem. 2006, 49, 2673-2676
10. A. P. Kozikowski, S. K. Chellappan, Y. Xiao, K. M. Bajjuri, H. Yuan, K. J. Kellar, P. A. Petukhov, ChemMedChem 2007, 2, 1157-1161
11. G. Roger, B. Lagnel, J. Rouden, L. Besret, H. Valette, S. Demphel, J. Gopisetti, C. Coulon, M. Ottaviani, L. A. Wrenn, S. R. Letchworth, G. A. Bohme, J. Benavides, M.-C. Lasne, M. Bottlaender, F. Dollé, Bioorg. Med. Chem. 2003, 11, 5333-5343. A small number of C4-substituted cytisine derivatives have been reported; see Ref. [4c] and [8a].
12. N. Houllier, S. Gouault, M.-C. Lasne, J. Rouden, Tetrahedron 2006, 62, 11679-11686
13. J. Rouden, A. Ragot, S. Gouault, D. Cahard, J.-C. Plaquevent, M.-C. Lasne, Tetrahedron: Asymmetry 2002, 13, 1299-1305
14. F. Frigerio, C. A. Haseler, T. Gallagher, Synlett 2010, 729-730.
15. C. Canu Boido, B. Tasso, V. Boido, F. Sparatore, Farmaco 2003, 58, 265-277.
16. D. Stead, P. O'Brien, Tetrahedron 2007, 63, 1885-1896.
17. For the synthesis of C4-substituted derivatives see B. T. O'Neill, D. Yohannes, M. W. Bundesmann, E. P. Arnold, Org. Lett. 2000, 2, 4201-4204
18. Ref. [4c]
19. P. Durkin, P. Magrone, S. Matthews. C. Dallanoce, T. Gallagher, Synlett 2010, 18, 2789-2791.
20. D. Yohannes, K. Procko, L. A. Lebel, C. B. Fox, B. T. O'Neill, Bioorg. Med. Chem. Lett. 2008, 18, 2316; as well as Ref. [8c].
21. D. Yohannes, C. P. Hansen, S. R. Akireddy, T. A. Hauser, M. N. Kiser, N. J. Gurnon, C. S. Day, B. Bhatti, W. S. Caldwell, Org. Lett. 2008, 10, 5353-5356.
22. A. B. Smit, N. I. Syed, D. Schaap, J. van Minnen, J. Klumperman, K. S. Kits, H. Lodder, R. C. van der Schors, R. van Elk, B. Sorgedrager, K. Brejc, T. K. Sixma, W. P. M. Geraerts, Nature 2001, 411, 261-268
23. K. Brejc, W. J. van Dijk, R. V. Klaassen, M. Schuurmans, J. van der Oost, A. B. Smit, T. K. Sixma, Nature 2001, 411, 269-276
24. P. H. N. Celie, S. E. van Rossum-Fikkert, W. J. van Dijk, K. Brejc, A. B. Smit, T. K. Sixma, Neuron 2004, 41, 907-914
25. Y. Bourne, T. T. Talley, S. B. Hansen, P. Taylor, P. Marchot, EMBO J. 2005, 24, 1512-1522
26. S. B. Hansen, G. Sulzenbacher, T. Huxford, P. Marchot, P. Taylor, Y. Bourne, EMBO J. 2005, 24, 3635-3646.
27. C. D. Dellisanti, Y. Yao, J. C. Stroud, Z. Z. Wang, L. Chen, Nat. Neurosci. 2007, 10, 953-962.
28. J. A. Abin-Carriquiry, M. P. Zunini, B. K. Cassels, S. Wonnacott, F. Dajas, Bioorg. Med. Chem. Lett. 2010, 20, 3683-3687.
29. D. Gray, T. Gallagher, Angew. Chem. 2006, 118, 2479-2483
30. Angew. Chem. Int. Ed. 2006, 45, 2419-2423.
31. T. Gallagher, I. Derrick, P. M. Durkin, C. A. Haseler, C. Hirschhäuser, P. Magrone, J. Org. Chem. 2010, 75, 3766-3774. Key step of our earlier method was the intramolecular 1,6-addition of a lactam enolate to a 2-pyridone (22 a → 23 a). This was unsuccessful for 22 b → 23 b and 22 c → 23 c where evidence was obtained for addition of the HMDS anion to the heterocycle.
32. All compounds described here are racemic. The synthesis of (R)- 5 a and nonnatural (+)-cytisine has been reported; see Ref. [14] and also:, M. H. Kim, Y. Park, B. S. Jeong, H. G. Park, S. S. Jew, Org. Lett. 2010, 12, 2826-2829.
33. A related sequence involving configurationally stable cis-piperidines has been described, see Ref. [8a] and, T. Honda, R. Takahashi, H. Namiki, J. Org. Chem. 2005, 70, 499-504.
34. For conditions used see the Supporting Information. Selective thionation of the lactam C=O of 19 using Lawesson's reagent failed (see the Supporting Information).
35. 2O caused degradation.
36. 50 of 85 n M (cf. (-)-cytisine 7.7 n M; A. Kennett, S. Wonnacott, C. Hirschhäuser, C. A. Haseler, T. Gallagher, unpublished results). Coe et al. have reported that varenicline is three-fold more potent than cytisine at α4β2 in rat cortex; see Ref. [2a].